Physician profile
Mark Zimmerman
NPI 1508842857
$225,125.10
in general payments reported to CMS, 2019-2025
18 companies · $58K in 2025
The $58K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $5,945 · 2021: $7,061 · 2022: $8,526 · 2023: $40K · 2024: $68K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Consulting Fee: $51K · Travel and Lodging: $35K · Food and Beverage: $4,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,033.00 |
| Consulting Fee | $51,328.75 |
| Travel and Lodging | $34,551.89 |
| Food and Beverage | $4,800.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110,906.17 | 2021-2025 | Caplyta |
| Otsuka Pharmaceutical Co., Ltd. | $26,264.75 | 2023 | Rexulti |
| Amgen INC. | $20,311.69 | 2019 | |
| Merck Sharp & Dohme LLC | $19,520.45 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $9,288.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,831.98 | 2023 | |
| Boehringer Ingelheim International Gmbh | $6,608.49 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $4,937.64 | 2019-2025 | Rexulti |
| Pfizer International LLC | $4,500.00 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,312.50 | 2019-2021 | |
| Sk Life Science, INC. | $3,200.00 | 2020 | |
| Biogen, INC. | $3,101.00 | 2022 | |
| Alkermes, INC. | $2,419.48 | 2020-2021 | |
| Abbvie INC. | $805.04 | 2024 | |
| Jazz Pharmaceuticals INC. | $50.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $28.21 | 2019 | |
| Axsome Therapeutics, INC. | $20.53 | 2023 | Auvelity |
| Novo Nordisk INC | $19.00 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.